查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587218

凝血因子集中市場：按凝血因子類型、產品劑型、應用和最終用戶分類 - 2025-2030 年全球預測

Coagulation Factor Concentrates Market by Type of Coagulation Factor (Factor IX concentrates, Factor VII concentrates, Factor VIII concentrates), Product Formulation, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年凝血因子濃縮物市值為86.6億美元，預計到2024年將達到88.4億美元，複合年成長率為7.46%，預計到2030年將達到143.4億美元。

凝血因子濃縮物在治療出血性疾病（例如A型血友病、馮維勒布蘭德病和其他凝血障礙）方面發揮重要作用。這些濃縮物是特定凝血因子的精製版本，用於補償患者凝血因子缺乏或功能障礙。對凝血因子濃縮物的需求源於對有效且有針對性的治療策略的需求，以控制出血事件並預防凝血病的長期併發症。其主要用途包括預防性治療、按需治療以及受影響患者的手術全期管理。主要最終使用者是醫院、專科診所和居家醫療機構。市場成長的推動因素包括出血性疾病意識的提高、生物技術的進步、醫療保健的改善以及血友病患病率的上升。重組 DNA 技術的創新、長效濃縮物的開發以及基因療法是該領域的一些最新機會。鼓勵公司專注於非因子療法的研究和開發以及改進的給藥方法，以鞏固其在這個快速成長的市場中的地位。然而，治療成本上升、替代治療方法的可用性、嚴格的監管核准以及新興市場的低認知度等挑戰可能會阻礙市場成長。該市場中未滿足的領域包括個人化醫療和開拓副作用較少的治療方法。此外，採用數位健康工具進行有效的疾病管理可能代表著一條巨大的成長道路。凝血因子濃縮物市場的特點是激烈的競爭和不斷的創新，以滿足患者和醫療保健提供者的微妙需求。推動成長的關鍵研究領域包括探索新的分子標靶、提高生產過程的永續性以及透過創新的交付平台和教育舉措提高患者的依從性。

主要市場統計
基準年[2023] 86.6億美元
預測年份 [2024] 88.4億美元
預測年份 [2030] 143.4億美元
複合年成長率（%） 7.46%

市場動態：針對快速發展的凝血因子濃縮物市場揭示的關鍵市場見解

供需的動態交互作用正在改變凝血因子濃縮物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 血友病和凝血障礙的盛行率
    • 加強生物技術研究與開發，開發有效的凝血因子濃縮物
    • 傾向於疾病的早期診斷和治療
  • 市場限制因素
    • 與凝血因子濃縮物合成相關的污染問題
  • 市場機會
    • 改良凝血因子濃縮物簡介
    • 基因治療取得重大進展
  • 市場挑戰
    • 嚴格的產品核可監管程序

波特五力：駕馭凝血因子濃縮物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對凝血因子濃縮物市場的影響

外部宏觀環境因素在塑造凝血因子濃縮物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解凝血因子濃縮物市場的競爭狀況

對凝血因子濃縮物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 定位矩陣凝血因子濃縮物市場供應商的績效評估

FPNV定位矩陣是評估凝血因子濃縮物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了凝血因子濃縮物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對凝血因子濃縮物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 血友病和凝血缺陷的盛行率
      • 加強生物技術研究與開發，開發有效的凝血因子濃縮物
      • 疾病的早​​期診斷和治療趨勢
    • 抑制因素
      • 與凝血因子濃縮物合成相關的污染問題
    • 機會
      • 改良凝血因子濃縮物介紹
      • 基因治療的重大進展
    • 任務
      • 嚴格的產品核可監管程序
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依凝血因子類型分類的凝血因子濃縮物市場

  • IX 因子 (FIX) 濃縮物
  • 因子 VII (FVII) 濃縮物
  • 因子 VIII (FVIII) 濃縮物
  • XIII 因子 (FXIII) 濃縮物

第7章 凝血因子濃縮物市場（依產品配方）

  • 血漿源性凝血因子濃縮物
  • 重組凝血因子濃縮物

第8章凝血因子集中市場：依應用分類

  • 血友病治療
  • 外科手術

第9章凝血因子濃縮物市場：依最終使用者分類

  • 家庭護理設置
  • 醫院
  • 專科診所

第10章美洲凝血因子濃縮物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太凝血因子濃縮物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲凝血因子濃縮物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Bayer AG
  • Bio Products Laboratory Limited
  • BIOGEN INC.
  • Biotest AG.
  • Cerus Corporation
  • Emergent BioSolutions Inc.
  • Kedrion SpA
  • LFB USA
  • Medscape Network
  • Novo Nordisk A/S
  • Octapharma USA, Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-DD0700E81E59

The Coagulation Factor Concentrates Market was valued at USD 8.66 billion in 2023, expected to reach USD 8.84 billion in 2024, and is projected to grow at a CAGR of 7.46%, to USD 14.34 billion by 2030.

Coagulation factor concentrates play a critical role in the management of bleeding disorders such as hemophilia A and B, von Willebrand disease, and other coagulation deficiencies. These concentrates are purified preparations of specific coagulation factors used to replace or support deficient or dysfunctional clotting factors in patients. The necessity for coagulation factor concentrates stems from the need for effective and targeted treatment strategies to manage bleeding episodes and prevent long-term complications of coagulation disorders. Their primary applications include prophylactic treatment, on-demand therapy, and perioperative management in affected individuals. The primary end-users comprise hospitals, specialty clinics, and home care settings. Market growth is significantly driven by increased awareness of bleeding disorders, advancements in biotechnology, improved healthcare access, and the rising prevalence of hemophilia. Innovations in recombinant DNA technology, the development of long-acting concentrates, and gene therapy are some of the latest opportunities in this field. Companies are recommended to focus on R&D for non-factor therapies and enhanced delivery methods to solidify their positions in this burgeoning market. However, challenges such as high cost of therapies, availability of alternative treatments, stringent regulatory approvals, and limited awareness in developing regions can impede market growth. Unaddressed areas in the market include personalized medicine and the development of therapies with fewer side effects. Moreover, embracing digital health tools for effective disease management can present substantial growth avenues. The coagulation factor concentrates market is characterized by robust competition and a constant push for innovation to meet the nuanced demands of patients and healthcare providers. Key research areas for driving growth include exploring novel molecular targets, improving the sustainability of production processes, and enhancing patient adherence through innovative delivery platforms and educational initiatives.

KEY MARKET STATISTICS
Base Year [2023] USD 8.66 billion
Estimated Year [2024] USD 8.84 billion
Forecast Year [2030] USD 14.34 billion
CAGR (%) 7.46%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Coagulation Factor Concentrates Market

The Coagulation Factor Concentrates Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of hemophilia and clotting deficiencies
    • Increase in biotechnology R&D to develop effective coagulation factor concentrates
    • Inclination toward early diagnosis and treatment of diseases
  • Market Restraints
    • Contamination issues associated with the synthesis of coagulation factor concentrate
  • Market Opportunities
    • Introduction of improved coagulation factor concentrates
    • Significant advancements in gene therapy
  • Market Challenges
    • Stringent regulatory procedure for product approval

Porter's Five Forces: A Strategic Tool for Navigating the Coagulation Factor Concentrates Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Coagulation Factor Concentrates Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Coagulation Factor Concentrates Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Coagulation Factor Concentrates Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Coagulation Factor Concentrates Market

A detailed market share analysis in the Coagulation Factor Concentrates Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Coagulation Factor Concentrates Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Coagulation Factor Concentrates Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Coagulation Factor Concentrates Market

A strategic analysis of the Coagulation Factor Concentrates Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Coagulation Factor Concentrates Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Bio Products Laboratory Limited, BIOGEN INC., Biotest AG., Cerus Corporation, Emergent BioSolutions Inc., Kedrion S.p.A, LFB USA, Medscape Network, Novo Nordisk A/S, Octapharma USA, Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Coagulation Factor Concentrates Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type of Coagulation Factor, market is studied across Factor IX (FIX) concentrates, Factor VII (FVII) concentrates, Factor VIII (FVIII) concentrates, and Factor XIII (FXIII) concentrates.
  • Based on Product Formulation, market is studied across Plasma-Derived Coagulation Factor Concentrates and Recombinant Coagulation Factor Concentrates.
  • Based on Application, market is studied across Hemophilia Treatment and Surgical Procedures.
  • Based on End-User, market is studied across Homecare Settings, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of hemophilia and clotting deficiencies
      • 5.1.1.2. Increase in biotechnology R&D to develop effective coagulation factor concentrates
      • 5.1.1.3. Inclination toward early diagnosis and treatment of diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Contamination issues associated with the synthesis of coagulation factor concentrate
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of improved coagulation factor concentrates
      • 5.1.3.2. Significant advancements in gene therapy
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory procedure for product approval
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Coagulation Factor Concentrates Market, by Type of Coagulation Factor

  • 6.1. Introduction
  • 6.2. Factor IX (FIX) concentrates
  • 6.3. Factor VII (FVII) concentrates
  • 6.4. Factor VIII (FVIII) concentrates
  • 6.5. Factor XIII (FXIII) concentrates

7. Coagulation Factor Concentrates Market, by Product Formulation

  • 7.1. Introduction
  • 7.2. Plasma-Derived Coagulation Factor Concentrates
  • 7.3. Recombinant Coagulation Factor Concentrates

8. Coagulation Factor Concentrates Market, by Application

  • 8.1. Introduction
  • 8.2. Hemophilia Treatment
  • 8.3. Surgical Procedures

9. Coagulation Factor Concentrates Market, by End-User

  • 9.1. Introduction
  • 9.2. Homecare Settings
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas Coagulation Factor Concentrates Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Coagulation Factor Concentrates Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Coagulation Factor Concentrates Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Bayer AG
  • 2. Bio Products Laboratory Limited
  • 3. BIOGEN INC.
  • 4. Biotest AG.
  • 5. Cerus Corporation
  • 6. Emergent BioSolutions Inc.
  • 7. Kedrion S.p.A
  • 8. LFB USA
  • 9. Medscape Network
  • 10. Novo Nordisk A/S
  • 11. Octapharma USA, Inc.
  • 12. Pfizer Inc.
  • 13. Takeda Pharmaceutical Company Limited
  • 14. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. COAGULATION FACTOR CONCENTRATES MARKET RESEARCH PROCESS
  • FIGURE 2. COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. COAGULATION FACTOR CONCENTRATES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. COAGULATION FACTOR CONCENTRATES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COAGULATION FACTOR CONCENTRATES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. COAGULATION FACTOR CONCENTRATES MARKET DYNAMICS
  • TABLE 7. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FACTOR IX (FIX) CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FACTOR VII (FVII) CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FACTOR VIII (FVIII) CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FACTOR XIII (FXIII) CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PLASMA-DERIVED COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. COAGULATION FACTOR CONCENTRATES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. COAGULATION FACTOR CONCENTRATES MARKET, FPNV POSITIONING MATRIX, 2023